1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Repurposed Promise In Competitive Indication

 
• By Jung Won Shin

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

liver
Hanmi’s First Major Licensing Out Deal For Years • Source: Shutterstock

Merck & Co., Inc. (known as MSD outside North America) and Hanmi Pharmaceutical Co., Ltd. have reached an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of non-alcoholic steatohepatitis (NASH), in a deal worth up to $870m.

The major transaction marks a significant turnaround for both Hanmi and the assets, after Janssen Pharmaceutical Cos

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia